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Abstract. Assessment of the malignant potential of parathyroid tumors in
the absence of metastases can be difficult using morphologic criteria
alone. In this study we have examined a total of 58 parathyroid tumors (31
benign, 15 malignant, and 12 equivocal) from 54 patients using immuno-
histochemistry with monoclonal antibodies directed against the retino-
blastoma (RB) protein and the cell cycle-associated antigen Ki-67 to
evaluate their role as diagnostic markers. RB protein immunoreactivity
was not useful for distinguishing between benign and malignant parathy-
roid tumors. Analysis of the proliferation marker Ki-67 showed that there
was a trend toward more intense staining in the malignant cases. The
Ki-67 labeling index was highest in the parathyroid cancers (median 33)
and lowest in the sporadic primary adenomas (median 2). An observation
that might have clinical implications is that tumors from patients with
familial hyperparathyroidism linked to chromosome 1q showed a high
Ki-67 index, indicating strong proliferative activity (median 25). This
correlates well with the clinical observation of tumors with malignant
potential in this syndrome. Because of the considerable overlap between
groups of tumors, Ki-67 is not suitable for definitive differentiation
between benign and malignant tumors. However, Ki-67 may give valuable
information about which patients should be followed more closely.
Parathyroid tumorigenesis is a complex process in which various
genetic abnormalities have been implicated [1–3]. Malignant
transformation of parathyroid tumors is a rare phenomenon, and
the incidence of parathyroid carcinoma in patients with primary
hyperparathyroidism (PHPT) is less than 1% [4]. Familial HPT is
associated with a number of disorders, such as multiple endocrine
neoplasia type I and II (MEN-I and MEN-II), neurofibromatosis
type 1 (NF1), and the hyperparathyroidism jaw tumor syndrome
(HPT-JT). Interestingly, parathyroid cancer seems to be associ-
ated with HPT-JT [5].
Clinically, patients with carcinoma present with symptomatic hy-
percalcemia, osteolytic bone changes, and renal impairment more
often than patients with benign forms of HPT [6, 7]. Parathyroid
carcinoma recurs locally or metastasizes to regional lymph nodes,
lungs, liver, and bone. Markedly elevated calcium levels, rather than
local tumor invasion or distant metastases, are the causes of death in
these patients [4, 7–10]. Because of the risk of recurrence patients
should be followed closely and repetitious surgical interventions be
performed when necessary and feasible. The optimal chance to
achieve complete cure for parathyroid cancer is when the tumor is
removed en bloc at the primary operation [11].
In the absence of invasion of adjacent organs or structures or
metastases, the diagnosis of cancer cannot be definitely established
based on histopathology [4]. Identification of molecular markers for
parathyroid malignancy would be of great importance in the clinical
management of these patients. A recent study has proposed that loss
of protein expression as well as somatic deletions of the retinoblas-
toma (RB) gene is diagnostic for parathyroid carcinoma [12]. Dele-
tions of the RB gene also occur in atypical recurrent parathyroid
disease [13]. These findings would give the RB gene a possible
diagnostic and prognostic role in the management of parathyroid
tumors [12]. However, later studies on parathyroid tumors using RB
immunohistochemistry have not been able to corroborate the find-
ings of Cryns et al. [14, 15].
Immunohistochemistry for measurement of proliferative activ-
ity and thus assessment of the biologic behavior of tumors is
widely used. The most reliable proliferation marker known so far
is the cell cycle-associated Ki-67 antigen [16]. The proliferation
index measured with Ki-67 in parathyroid tumors has been shown
to be helpful for classifying these tumors [14, 17]. In this study we
have examined 58 parathyroid tumors using immunohistochemis-
try with monoclonal antibodies directed against the RB and Ki-67
nuclear proteins to evaluate their role as diagnostic markers in
benign and malignant parathyroid tumors.
Materials and Methods
Tumor Material and Histopathology
A total of 58 tumors (31 benign, 15 malignant, 12 equivocal) from
54 patients with HPT were examined. The malignant and equiv-Correspondence to: F. Farnebo, M.D., Ph.D.
ocal cases were collected worldwide (see Acknowledgments), and
the histopathology and clinical course of these cases were previ-
ously published [18]. Fifteen patients were diagnosed as having
unequivocal parathyroid cancer and had either a microscopically
infiltrative growth pattern, evidence of recurrence, or both. These
tumors also often showed other pathologic features that occur in
parathyroid cancer, such as marked fibrosis often with hyaline
bands splitting the parenchyma and focally spread necrosis as well
as cytologic features such as marked cellular atypia, macro-
nucleoli, and large nuclei. The DNA distribution pattern was
significantly abnormal compared to the so-called equivocal cases
previously reported [18].
Twelve patients had tumors that exhibited histopathologic
features of cancer, as described above, but lacked a microscopic
infiltrative growth pattern or evidence of recurrence (i.e., equiv-
ocal cases). Mitotic figures were also less frequent in these
equivocal tumors than in the cancers [18].
For comparison, 31 benign tumors of different genetic back-
ground were selected. These tumors originated from eight pa-
tients with sporadic HPT (eight glands), three patients with
secondary HPT (seven glands), seven patients with familial
MEN-I (seven glands), five patients from two families with HPT
linked to the HRPT2 locus on chromosome 1q (five glands), two
patients who had previously undergone radiation treatment to the
neck (two glands), and two patients with familial hypocalciuric
hypercalcemia (FHH) (two glands).
RB and Ki-67 Immunostaining
Serial sections from representative formalin-fixed, paraffin-em-
bedded blocks of tumors were screened for expression of RB and
Ki-67. The RB monoclonal antibody PMG3-245 (PharMingen,
San Diego, CA, USA) specifically targets the epitope from amino
acid 300 to 380 of the pRB protein and recognizes phosphorylated
as well as nonphosphorylated protein. The MIB-1 monoclonal
antibody (Immunotech, Marseille, France) recognizes a determi-
nant of the Ki-67 antigen. A 1:200 dilution of the RB and a 1:150
dilution of the MIB-1 antibodies were used. Deparaffinized
sections 4 mm thick were rehydrated, and endogenous peroxidase
activity was suppressed with 0.5% H2O2 for 30 minutes. The
sections were then heated in citrate buffer (pH 6.0) for 2 3 5
minutes at 750 W in a household microwave oven to intensify the
immunohistochemical result [19]. Primary antiserum was added
overnight at 4° to 8°C, and the site of antigen–antibody binding
was visualized according to the avidin-biotin-peroxidase complex
method (ABC Elite, Vector Laboratories, Burlingame, CA,
USA), following the manufacturer’s instructions. Diaminobenzi-
dine (DAB) was used as chromogen, and the sections were
counterstained with Mayers hematoxylin. A positive control
(lymph node metastasis of breast cancer) was included in each
experiment.
All sections were scored by at least two independent investiga-
tors. The RB nuclear immunostaining was scored according to the
following criteria: 0, absent; 1, weak; 11, moderate; 111,
strong staining (Fig. 1). Ki-67 positivity was quantified by counting
a total of 1000 cells from multiple areas of the slide in a
randomized fashion. The results are given as the median and
range. Differences between groups was tested using the Mann-
Whitney U-test (two unpaired groups) or the Kruskal-Wallis test
(more than two groups).
Results
The results of the staining for RB are summarized in Table 1 and
exemplified in Figure 1. The tumors displayed a wide range of
staining intensity, with no diagnostic specific pattern seen in any of
the subgroups. Figures 1c and 1d show RB and Ki-67 staining of
a tumor from a 52-year-old male patient where the initial diag-
nosis was consistent with a parathyroid adenoma. However, soon
after the operation the patient became hypercalcemic and under-
went two cervical explorations for recurrent disease. At this time
the tumors fulfilled all criteria of parathyroid cancer. The immu-
nohistochemical analysis was performed on tumor tissue from the
time of reexploration. The tumor was scored as RB 11 and had
a Ki-67 index of 133. This patient died from unremitting disease
after a period of 30 months.
The scoring of the Ki-67 staining is shown in Figure 2 and
exemplified in Figure 1. The median Ki-67 indexes for cancer,
equivocal cases, sporadic adenomas, secondary HPT, MEN-I and
familial HPT were 33, 14, 2, 6, 7, and 25, respectively. There is a
statistically significant difference between these groups (p 5 0.04).
The difference between the cancer groups and the sporadic
adenomas is highly significant (p 5 0.007).
The five tumors from patients with familial PHPT linked to the
HRPT2 locus on chromosome 1q were histopathologically diag-
nosed as benign lesions. Ki-67 staining of a parathyroid tumor
from a patient with familial HPT-JT syndrome is shown in Figure
1f. The patient is a 35-year-old man who was operated on at age
26 (1989) for a fast-growing tumor in the left maxilla. During
hospitalization PHPT was diagnosed, and at neck exploration a
2.35-g abnormal parathyroid gland was removed. Since the para-
thyroidectomy the patient has remained normocalcemic but has
developed another large maxillary tumor that has also been
removed [20]. The Ki-67 indexes of the two tumors from patients
who had previously undergone radiation therapy were 2 and 36.
The two parathyroid glands from patients with FHH had indexes
of 19 and 16.
The relation between RB staining and Ki-67 index is presented
in Figure 3. Tumors lacking RB staining also had the lowest Ki-67
index.
Discussion
The RB gene is a tumor-suppressor gene with a growth-inhibitory
effect in the cell cycle. It has been implicated in the pathogenesis
of a number of human cancers [21, 22]. Our study shows that RB
immunohistochemical staining cannot be used to distinguish
between benign and malignant parathyroid tumors. The results
markedly contrast with those of Cryns et al. [12] but are in
agreement with the study performed by Lloyd et al. [14]. A
possible explanation for the discrepancy is that the former authors
used a polyclonal antibody, whereas in the latter study and in the
present study monoclonal antibodies were used. How the slides
are stored prior to the immunostaining may also affect the results
[23].
In some parathyroid carcinomas and adenomas RB was
strongly positively stained, whereas in others it was not stained. It
is not known what causes the low RB protein expression. One
possible explanation is less stable mRNA or transcriptional reg-
ulation. Another explanation would be loss of one of the alleles at
the RB locus on chromosome 13q14. Such losses have been
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demonstrated in both benign and malignant parathyroid tumors
[12, 13]. Additional studies of loss of heterozygosity (LOH) for
markers in the RB gene in this laboratory showed that some
carcinomas retain both alleles (data not shown), whereas LOH
could be demonstrated in some benign tumors [2].
This study indicates that the proliferation marker Ki-67 may be
of greater value for discriminating between benign and malignant
tumors. However, the precise role of Ki-67 is not immediately
evident, as there is a considerable overlap between various
tumors.
Previous studies on the proliferative activity of parathyroid
glands using tritiated thymidine have shown that the labeling
index in sporadic adenomas and in hyperplastic glands from
patients with secondary HPT is extremely low, approximately 0.25
labeled cells/1000 [24, 25]. The 10-fold higher frequency seen in
this study may be due to labeling of a greater fraction of the cell
cycle by Ki-67 [26]. An even higher Ki-67 index in adenomas was
reported by Abbona et al. (mean 32.8) [17] and Lloyd et al. (mean
24) [14]. A significant difference between clinically evident cancers
and adenomas was demonstrated in both these studies. In the
work by Lloyd et al. [14] there was a certain overlap between the
malignant and benign tumors. Abbona et al. [17] reported only
mean values and no standard deviation, which makes the degree
of overlap difficult to evaluate. Wang et al. found a Ki-67 index of
less than 10 in 13 of 21 adenomas. Two adenomas had an index
exceeding 50 [27].
When the equivocal cases and unequivocal parathyroid cancers
were compared no statistical difference could be demonstrated,
although numerically the median value was lower among the
equivocal cases. This is in accordance with the findings of Abbona
et al. and Lloyd et al., who did not find any statistical difference
between tumors from patients with an aggressive or an indolent
clinical course. The same tendency could be seen in the present
investigation. It is therefore possible that among the cases classi-
Fig. 1. Microphotographs of
parathyroid tumors stained for RB
(left) and Ki-67 (right). a, b. Tumor
from a patient with HPT-JT
syndrome (RB staining 1, Ki-67
index 36). c, d. Patient with
parathyroid cancer (RB staining
11, Ki-67 index 133). e, f. Patient
with parathyroid cancer (RB
staining 111, Ki-67 index 90).
70 World J. Surg. Vol. 23, No. 1, January 1999
fied as “equivocal” some tumors in fact were benign. Further
support for this statement is the mean disease-free follow-up of 12
years. The Ki-67 index of the MEN-I tumors was in the same
range as that of the adenomas underlining the benign nature of
these tumors.
An observation that might have clinical implications is that
tumors from patients with familial HPT linked to chromosome 1q
show intense staining for Ki-67, indicating strong proliferative
activity. This correlates well with the clinical observation of more
aggressive tumors with malignant potential in this syndrome.
Parathyroid cancer has been reported to occur in 3 of the 12
described families linked to 1q [28–30]. However, none of the
tumors analyzed in this study showed any histopathologic malig-
nant features. Patients with HPT-JT can develop multiple adeno-
mas, and one patient was operated on twice. The median fol-
low-up of these patients is 8 years, with no sign of malignant
transformation.
Dionisio et al. [31] reported a high Ki-67 index in one case of
secondary HPT where a single parathyroid gland transplanted to
the arm showed signs of excessive growth. Based on the high Ki-67
index the authors concluded that that gland must represent
parathyroid cancer. In view of the overlap between different
groups of parathyroid tumors seen in the present investigation, we
would be hesitant to draw such definitive conclusions from a high
Ki-67 index. Apparently, some tumors of secondary HPT, with no
suspicion of cancer, have high proliferative activity and might not
be suitable for grafting.
Conclusions
This study shows that RB cannot be used to distinguish between
benign and malignant parathyroid tumors. Nor can the prolifera-
tion marker Ki-67 be used for safe differentiation between benign
and malignant tumors in a single specific case. On the other hand,
Ki-67 gives additional information that may be used to decide
which patients must be followed more closely, especially those
with familial HPT and in cases where the histopathology remains
equivocal and clinical signs of malignancy are lacking.
Résumé
Evaluer le potentiel malin des tumeurs de la parathyroı̈de en
l’absence de métastases peut être difficile en se basant unique-
ment sur des critères morphologiques. Dans cette étude nous
avons examiné 58 tumeurs de la parathyroı̈de (31 tumeurs bé-
nignes, 15 malignes et 12 équivoques) chez 54 patients par des
tests immunochimiques utilisant des anticorps monoclonaux con-
tre la protéine de rétinoblastome (RB) et l’antigène cellulaire
Ki-67 pour évaluer leur rôle potentiel de marqueur diagnostique.
Du point de vue immunochimique, la protéine RB n’était pas très
utile pour distinguer entre tumeur bénigne et maligne de la
Table 1. RB staining of parathyroid tumors.
Diagnosis Median age at operation
Immunoreactivity of RB
0 1 11 111
Parathyroid cancer 59 4 7 4
Equivocal cases 48.5 4 3 2 3
Sporadic HPT 56.5 6 1 1
SHPT 52 1 4 1 1
MEN-I 38 3 2 2
FHPT-1q 25 2 3
Radiation associated HPT 63.5 1 1
FHH 53.5 2
Total 21 19 13 5
0: absent; 1: weak; 11: moderate; 111: strong nuclear staining.
FHPT-1q: familial hyperparathyroidism linked to 1q; FHH: familial hypocalciuric hypercalcemia; MEN-I: multiple endocrine neoplasia type I; RB:
retinoblastoma; SHPT: secondary hyperparathyroidism.
Fig. 2. Box plot of Ki-67 index for six groups of parathyroid (PT) tumors.
Median and interquartile ranges are in the box; 10th and 90th percentiles
are indicated by transverse bars; single values outside the 10th and 90th
percentiles are shown by circles.
Fig. 3. Box plot of Ki-67 index for 57 parathyroid tumors grouped
according to their immunoreactivity to RB protein. Median and interquar-
tile ranges are in the box; 10th and 90th percentiles are indicated by
transverse bars; single values outside 10th and 90th percentiles are shown
by circles.
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parathyroı̈de. L’analyse du marqueur de la prolifération Ki-67 a
montré que la coloration était plus prononcée en cas de tumeur
maligne. L’index d’étiquetage au marqueur Ki-67 était le plus
élevé en cas de cancer de la parathyroı̈de (médiane 33) et le plus
bas en cas d’adénome primitif sporadique (médiane 2). Un fait
qui pourrait avoir un intérêt clinique est que les tumeurs des
patients se présentant avec un hyperparathyroı̈disme familial lié
au chromosome 1q avaient un indexe Ki-67 élevé indiquant une
activité de prolifération importante (médiane 25). Ceci est en
corrélation avec l’observation clinique des tumeurs ayant un
potentiel malin dans ce syndrome. En raison de la faible spéci-
ficité entre les groupes, l’utilisation du marqueur Ki-67 n’est pas
adaptée pour différencier entre les tumeurs bénignes et malignes.
Le marqueur Ki-67, cependant, pourrait être utile comme indica-
teur des patients qui devraient être suivis de près.
Resumen
Basándose exclusivamente en criterios morfológicos, es difı́cil, si
no existen metástasis, diagnosticar la posible malignización de los
tumores paratiroideos. Por ello, en el presente estudio, hemos
tratado de valorar, mediante técnicas immunohistoquı́micas, el
papel que pueden tener, como marcadores diagnósticos, los
anticuerpos monoclonales directos contra la proteı́na del retino-
blastoma (RB) y los antı́genos, asociados al ciclo celular, Ki-67.
Nuestra casuı́stica comprende 54 pacientes, con 58 tumores
paratiroideos: 31 benignos, 15 malignos y 12 de naturaleza
incierta. La immunorreactividad de la proteı́na RB no fue útil
para dilucidar la benı́gnidad o malı́gnidad de los tumores para-
tiroideos. El ı́ndice de proliferación de los antı́genos Ki-67 fue
alto, en los cánceres paratiroideos (media 33) y bajo, en los
esporádicos adenomas primarios (media 2). Observamos un he-
cho que puedo tener importancia clı́nica; en tumores de pacientes
con hiperparatiroidismo familiar ligado al cromosoma 1q, el
ı́ndice Ki-67 (media 25) fue muy alto, lo que indica una gran
actividad celular proliferativa. Este hecho guarda estrecha rela-
ción con el sı́ndrome de hiperparatiroidismo familiar, en el que se
observa una evidente predisposición a la malignización. El Ki-67
no es un test válido para el diagnóstico diferencial definitivo entre
tumores malignos y benignos, debido al solapamiento de los
valores detectados entre ambos grupos. Sin embargo, el Ki-67
proporciona una información útil para detectar, a aquellos paci-
entes que han de tener un seguimiento clı́nico más estricto, con
objeto de diagnosticar precozmente una posible malignización
tumoral.
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The diagnosis of parathyroid carcinoma can be difficult his-
topathologically in the absence of invasion of adjacent organs or
structures, metastatic disease or both [1, 2]. The presence of
certain histologic features including cellular and nuclear pleomor-
phism and general tumor size have not been particularly useful for
making this diagnosis. Mitotic counts may be helpful for evaluat-
ing the malignant potential of parathyroid tumors; but several
variable such as tissue preservation can influence this analysis and,
in many endocrine tumors, including those of the parathyroid,
mitoses may be difficult to find. In recent years, various prolifer-
ation markers associated with the cell cycle that can be detected
by immunohistochemistry in formalin-fixed paraffin-embedded
tissue sections have been used for histopathologic studies [3].
Antibodies to Ki-67 and a cell cycle protein detected in all phases
of the cell cycles except G0 [4, 5] have been used in attempts to
distinguish between low-grade and high-grade tumors as well as
adenomas and carcinomas.
In this issue Farnebo et al. examined retinoblastoma (RB) and
Ki-67 expression as potential diagnostic markers of parathyroid
tumors in a series of 58 tumors (31 benign, 15 malignant, 12
equivocal). RB protein immunoreactivity was not useful for
distinguishing between benign and malignant parathyroid tumors.
However, Ki-67 analysis showed that there was a trend toward a
higher percentage of cells staining in the malignant cases, with a
median Ki-67 labeling index of 33 in parathyroid carcinomas and
of 2 in sporadic primary adenomas. Interestingly, patients with
familial hyperparathyroidism also had a high Ki-67 labeling index,
with a mean of 25, which correlates with the clinical observation of
tumors with malignant potential associated with this syndrome.
The finding of differences in Ki-67 labeling indices between
adenomas and carcinomas agrees with that of other recent reports
[6, 7].
Can Ki-67 be used to distinguish between benign and malignant
parathyroid tumors? The authors correctly conclude that it cannot
because of the considerable overlap in Ki-67 indices in different
groups of tumors. A confounding variable in this study is the large
group of patients (n 5 12) with a diagnosis of equivocal tumors.
Unfortunately, follow-up information was not available to deter-
mine if these cases were truly benign or malignant, as it could have
helped clarify other aspects of the study.
Some significant questions must be addressed to learn more
about the utility of Ki-67. The first is the function of Ki-67 in the
cell cycle. This important issue remains unresolved 14 years after
the antibody was first described [4, 5]. It has been proposed that
Ki-67 functions as a timer molecule in the cell cycle [8]. Because
of the evolutionary conservation of Ki-67 antigen in many species
and its expression in both benign and malignant cells, it has also
been suggested that Ki-67 has an important role in the regulation
of cell proliferation, although some studies with cell hybrids have
shown cell proliferation in the absence of Ki-67 antigen [8]. The
recent cloning of the Ki-67 gene has shown that it plays a pivotal
role in maintaining cell proliferation [5], but its exact function
remains unknown.
The second question is whether analysis of Ki-67 can be
combined with that of other cell cycle proteins, such as p27 [9],
topoisomerase II-alpha [10], and the many other cell cycle gene
products that have recently been cloned to provide more of a
definitive differentiation between benign and malignant tu-
mors. This question will only be answered by future studies,
which the paper by Farnebo et al. should stimulate. While we
await future studies, we can agree with the conclusions of
Farnebo et al. that Ki-67 can provide valuable information
about which patients with parathyroid tumors should be fol-
lowed more closely.
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